Maegim한국어

아이진

185490KOSDAQSector: Pharma & Biotech
₩1,500 1.15%Market cap ₩64.8BAs of Jul 21, 2026 close · updated once daily
C
Grade C44.1 ptsTop 64% of 2,523 stocks
Financial strength
48.1
Growth momentum
50.9
Price attractiveness
34.6

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

48.1
How much debt does it carry relative to equity?
Debt-to-equity ratio
25.4%
Above median · Top 24.6% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
476.3%
Above median · Top 27.4% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-276.2%
Below median · Top 83.3% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-27.5%
Below median · Top 72.2% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original

2

Growth momentum

50.9
How much did revenue grow in a year?
Revenue growth (YoY)
6.3%
Below median · Top 50.9% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
-12.3%
Below median · Top 86% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
25.7%
Above median · Top 32.8% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
59.1%
Above median · Top 26.6% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original

3

Price attractiveness

34.6
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Below median · Top 85.2% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
1.14x
Above median · Top 45.7% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15